MX2018004547A - Nuevos anticuerpos fv multivalentes. - Google Patents
Nuevos anticuerpos fv multivalentes.Info
- Publication number
- MX2018004547A MX2018004547A MX2018004547A MX2018004547A MX2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A
- Authority
- MX
- Mexico
- Prior art keywords
- diabody
- multivalent
- antibodies
- chain
- scfv
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15189665.1A EP3156417A1 (en) | 2015-10-13 | 2015-10-13 | Multivalent fv antibodies |
| PCT/EP2016/074642 WO2017064221A1 (en) | 2015-10-13 | 2016-10-13 | Multivalent fv antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004547A true MX2018004547A (es) | 2018-11-09 |
Family
ID=54325413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004547A MX2018004547A (es) | 2015-10-13 | 2016-10-13 | Nuevos anticuerpos fv multivalentes. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11572415B2 (enExample) |
| EP (2) | EP3156417A1 (enExample) |
| JP (1) | JP6936497B2 (enExample) |
| KR (1) | KR20180057720A (enExample) |
| CN (1) | CN108473577A (enExample) |
| AU (1) | AU2016336866B2 (enExample) |
| BR (1) | BR112018007445A2 (enExample) |
| CA (1) | CA3001765A1 (enExample) |
| IL (1) | IL258638B2 (enExample) |
| MX (1) | MX2018004547A (enExample) |
| SG (2) | SG10202004094VA (enExample) |
| WO (1) | WO2017064221A1 (enExample) |
| ZA (1) | ZA201802543B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201890041A1 (ru) | 2015-06-15 | 2018-07-31 | Нумаб Инновейшн Аг | Гетеродимерный полиспецифичный формат антител |
| CN110799540B (zh) * | 2017-06-25 | 2024-02-13 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
| CA3090464A1 (en) | 2018-03-14 | 2019-09-19 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| AU2019243453B2 (en) * | 2018-03-27 | 2024-05-02 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
| US20240132626A1 (en) * | 2018-04-13 | 2024-04-25 | Eli Lilly And Company | Fab-Based Trispecific Antibodies |
| MX2020010728A (es) | 2018-04-13 | 2020-11-06 | Affimed Gmbh | Constructos de fusion de anticuerpos que se acoplan a celulas nk. |
| KR20200143730A (ko) * | 2018-04-17 | 2020-12-24 | 인벤라 인코포레이티드 | 3가 삼중 특이성 항체 구조물 |
| KR20210052494A (ko) | 2018-08-27 | 2021-05-10 | 아피메트 게엠베하 | 항체 구조물이 사전 로드된 동결 보존된 nk 세포 |
| CN115066274A (zh) * | 2019-09-25 | 2022-09-16 | 斯图加特大学 | 三价结合分子 |
| CN114502203B (zh) * | 2019-11-06 | 2024-07-19 | 成都百利多特生物药业有限责任公司 | 制导和导航控制蛋白及其制备和使用方法 |
| WO2021130383A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| TWI874613B (zh) * | 2020-03-17 | 2025-03-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| CA3203468A1 (en) * | 2020-12-03 | 2022-06-09 | Amgen Inc. | Immunoglobuline constructs with multiple binding domains |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| MX2024003808A (es) * | 2021-09-29 | 2024-06-11 | Modex Therapeutics Inc | Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos. |
| CN114316060B (zh) * | 2021-12-15 | 2023-06-13 | 北京市肿瘤防治研究所 | 抗人cd19与cd206双特异性抗体及其制备方法和应用 |
| US20230272069A1 (en) * | 2022-02-28 | 2023-08-31 | Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences | Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025235413A1 (en) * | 2024-05-05 | 2025-11-13 | Duke University | Compositions targeting cancer antigens and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| EP0739350B1 (en) * | 1994-01-07 | 2008-02-27 | Mochida Pharmaceutical Co., Ltd. | Ligand that binds fas antigen |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| AU2001270609A1 (en) * | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| EP1293514B1 (en) * | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
| US20030162709A1 (en) | 2001-12-26 | 2003-08-28 | Edmund Rossi | Methods of generating multispecific, multivalent agents from VH and VL domains |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| TW200808351A (en) * | 2006-07-13 | 2008-02-16 | Chugai Pharmaceutical Co Ltd | Cell death-inducing agents |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| GB201003701D0 (en) * | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| FR2959416B1 (fr) * | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
| WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| TWI803876B (zh) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| RU2693078C2 (ru) * | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| HK1216894A1 (zh) | 2012-12-28 | 2016-12-09 | Abbvie Inc. | 多價結合蛋白組合物 |
| US20150017120A1 (en) * | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| EA201890041A1 (ru) * | 2015-06-15 | 2018-07-31 | Нумаб Инновейшн Аг | Гетеродимерный полиспецифичный формат антител |
-
2015
- 2015-10-13 EP EP15189665.1A patent/EP3156417A1/en not_active Withdrawn
-
2016
- 2016-10-13 EP EP16791328.4A patent/EP3362478A1/en not_active Withdrawn
- 2016-10-13 IL IL258638A patent/IL258638B2/en unknown
- 2016-10-13 CA CA3001765A patent/CA3001765A1/en active Pending
- 2016-10-13 AU AU2016336866A patent/AU2016336866B2/en not_active Ceased
- 2016-10-13 CN CN201680073236.5A patent/CN108473577A/zh active Pending
- 2016-10-13 SG SG10202004094VA patent/SG10202004094VA/en unknown
- 2016-10-13 WO PCT/EP2016/074642 patent/WO2017064221A1/en not_active Ceased
- 2016-10-13 SG SG11201803083XA patent/SG11201803083XA/en unknown
- 2016-10-13 JP JP2018519031A patent/JP6936497B2/ja active Active
- 2016-10-13 BR BR112018007445A patent/BR112018007445A2/pt not_active Application Discontinuation
- 2016-10-13 MX MX2018004547A patent/MX2018004547A/es unknown
- 2016-10-13 KR KR1020187013310A patent/KR20180057720A/ko not_active Ceased
-
2018
- 2018-04-11 US US15/950,733 patent/US11572415B2/en active Active
- 2018-04-17 ZA ZA2018/02543A patent/ZA201802543B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL258638A (en) | 2018-06-28 |
| RU2018126966A (ru) | 2020-02-10 |
| BR112018007445A2 (pt) | 2019-12-10 |
| RU2018126966A3 (enExample) | 2020-04-20 |
| IL258638B (en) | 2022-12-01 |
| ZA201802543B (en) | 2020-01-29 |
| CA3001765A1 (en) | 2017-04-20 |
| US20190040155A1 (en) | 2019-02-07 |
| SG10202004094VA (en) | 2020-05-28 |
| AU2016336866B2 (en) | 2023-05-25 |
| SG11201803083XA (en) | 2018-05-30 |
| EP3362478A1 (en) | 2018-08-22 |
| JP2018537415A (ja) | 2018-12-20 |
| US11572415B2 (en) | 2023-02-07 |
| AU2016336866A1 (en) | 2018-05-10 |
| EP3156417A1 (en) | 2017-04-19 |
| JP6936497B2 (ja) | 2021-09-15 |
| CN108473577A (zh) | 2018-08-31 |
| WO2017064221A1 (en) | 2017-04-20 |
| IL258638B2 (en) | 2023-04-01 |
| KR20180057720A (ko) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004547A (es) | Nuevos anticuerpos fv multivalentes. | |
| PH12018500635A1 (en) | Bispecific antibodies specific for pd1 and tim3 | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| DK3638698T3 (da) | Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter | |
| NZ732628A (en) | Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof | |
| BR112018015480A2 (pt) | proteínas de ligação ao antígeno que se ligam a pd-l1 | |
| NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
| IL291545A (en) | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
| MX2018001566A (es) | Construcciones de union a antigeno para moleculas diana. | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
| HK1218930A1 (zh) | 新型多特异性结构 | |
| MX2015012540A (es) | Ratón de cadena ligera común. | |
| WO2016205427A3 (en) | Binding proteins against vegf, pdgf, and/or their receptors | |
| EA201990673A1 (ru) | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты | |
| IL278244A (en) | Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof | |
| WO2016100533A3 (en) | Intercalated single-chain variable fragments | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| EP3144676A4 (en) | Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer | |
| MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
| WO2021041300A3 (en) | Bispecific antibodies and uses thereof | |
| WO2020023619A3 (en) | Blood brain barrier selective antibodies and methods of use | |
| AR107083A1 (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos |